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S U M M A R Y
Introduction: Outpatient parenteral antibiotic therapy (OPAT) has become established as a standard of
care in most Australian hospitals to treat a variety of infections. Since 1998, the Alternate Site Infusion
Service (ASIS) has provided an OPAT service to ﬁve hospitals in southern Brisbane, Queensland, using
predominantly a patient or carer administration model (self-administered, S-OPAT). The aim of this
study was to evaluate outcomes of our S-OPAT programme.
Methods: Consecutive patients treated by ASIS at the Princess Alexandra Hospital from January 1,
2011 to December 31, 2011 were reviewed. Data on patient demographics, diagnoses, microbiology,
antimicrobial therapy, duration, outcome, and complications were sourced from a prospectively
collected database and from patient medical records.
Results: There were 150 episodes involving 144 patients resulting in 3520 days of OPAT; the median
duration on the programme was 22 days (range 4–106 days). Patient or carer administration occurred in
the majority of episodes. The most common indication by far was bone or joint infection (47% of
patients), followed by infective endocarditis (9%). Staphylococcus aureus was the most frequently treated
organism. The overall cure rate was 93%. On multivariate analysis, patients with two or more
comorbidities had an increased risk of failure. Line-related complications occurred in 1.4/1000 catheter-
days. Rash was the most common drug-related event. Despite the extensive use of broad-spectrum
antibiotics there were no cases of Clostridium difﬁcile infection during therapy and for up to 28 days post
cessation of intravenous antibiotics. The cost of OPAT per patient excluding drug administration and
home visits was approximately A$ 150.00/day, signiﬁcantly lower than the cost of an inpatient bed,
which is estimated to be A$ 500–800/day.5
Conclusion: OPAT using a patient or carer administration model is an effective and safe option for the
management of selected patients with infection requiring intravenous antibiotics.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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The ﬁrst reports of outpatient parenteral antibiotic therapy
(OPAT) came from the USA in the 1970s. Since then, OPAT has been
adopted worldwide and in Australia1–5 in various healthcare
settings.6–10 With appropriate patient selection, it has been shown
to be safe, efﬁcacious, and cost-effective.9–14 The ability to manage
patients in the community setting provides the freedom for
patients to return to work or educational facilities, reduces
pressure on hospital bed utilization, and reduces the risk of
developing nosocomial infections.9–13* Corresponding author.
E-mail address: subedi_82@yahoo.com (S. Subedi).
http://dx.doi.org/10.1016/j.ijid.2014.11.021
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).There are various models of care for OPAT, which include
hospital-based infusion centres, nursing outreach services to
patient homes for the administration of antibiotics, and adminis-
tration by self or family members.15 In Australia, most hospitals
provide hospital-centred nursing outreach programmes to patient
homes for the administration of antibiotics,1,2 which allows daily
direct supervision of the patient. However, the nursing costs in this
model can be signiﬁcant.15 Self-administration of intravenous
antibiotic therapy involves training the patient or their carer to
administer parenteral antibiotics that are pre-packaged ready for
use with ambulatory devices. The reduction in nursing costs and
increased patient autonomy are advantages of this model,
although adequate patient or carer training is essential to facilitate
drug administration in a safe and effective manner with minimal
complications.15–17 A peripherally inserted central catheter (PICC),ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Antibiotics can be administered as intermittent or continuous
infusions via an electronic pump or elastometric device.18,19
This is the ﬁrst report from an Australian hospital on outcomes
of a successful self-administered OPAT (S-OPAT) programme. The
results of this study will provide assistance to clinicians and
administrators who are involved in making decisions regarding the
development of future hospital services.
2. Methods
We reviewed patients treated by the Princess Alexandra
Hospital Alternate Site Infusion Service (ASIS) from January 1,
2011 to December 31, 2011. Information on patient demographics,
diagnoses, microbiology, antimicrobial therapy, duration, compli-
cations, and outcome were obtained from a prospectively collected
database and by reviewing the patient medical records. The Metro
South Health Services District Human Research Ethics Committee
granted ethics approval for the study (HREC/12/QPAH/38). The
statistical analysis was performed using Stata v. 11 (StataCorp LP,
College Station, TX, USA). A multivariate logistic regression model
was developed to identify potential risk factors for treatment
failure. Odds ratios (OR) with 95% conﬁdence intervals (95% CI)
were reported. A p-value of <0.05 was considered statistically
signiﬁcant.
2.1. Deﬁnitions
Success was deﬁned as cure or a major improvement as shown
by clinical progress, a signiﬁcant decrease in C-reactive protein,
and the absence of relapse within 28 days of cessation of
intravenous antibiotics. Although the majority of patients were
continued on oral antibiotics at the end of OPAT, monitoring of this
was not included in the present study. Failure occurred when the
prescribed course of OPAT did not result in cure or a major
improvement as deﬁned by criteria used in a previous study:2 (1)
there was a need to continue intravenous therapy beyond the
original prescribed course; (2) there was a need for unanticipated
surgery for source control within 4 weeks of completion of the
originally prescribed intravenous course; (3) hospital re-admission
related to OPAT complications; or (4) any evidence of relapse or
recurrence of infection within 4 weeks of completion of the
originally prescribed course. Drug-related complications included
rash, hepatitis, gastrointestinal symptoms, Clostridium difﬁcile
infection, and acute kidney injury requiring either cessation or a
change of parenteral antibiotics. Line-related complications
included line infection, thrombosis, inadvertent removal of the
intravenous access by the patient, and lymphatic leakage.
Administration was categorized as either a 24-h continuous
infusion or intermittent boluses.
2.2. Setting
Princess Alexandra Hospital is one of three tertiary hospitals in
Brisbane, Queensland and provides care in all major adult
specialties excluding obstetrics. The hospital has 780 beds and
provides an extensive range of acute medical, surgical, trauma,
mental health, cancer, and rehabilitation services, as well as a
state-wide transplantation service for livers, kidneys, bone,
cartilage, and corneas. ASIS is an OPAT service that was established
at the Princess Alexandra Hospital in 1998. ASIS is integrated
within the Infectious Diseases Department at the Princess
Alexandra Hospital and consists of a multidisciplinary team that
includes medical, nursing, and pharmacy personnel. Since then, the
service has expanded to provide services to Ipswich, Logan, Queen
Elizabeth II, and Redland hospitals. A visiting consultation serviceis provided to the other hospitals by infectious diseases physicians
from Princess Alexandra Hospital.
2.3. Patient selection
An infectious diseases physician or a registrar assessed the
suitability and medical stability of patients for enrolment into ASIS.
Further in-hospital assessment of suitability was performed by
dedicated ASIS nursing staff, and the patient was provided with
training on self-administration of antibiotics prior to discharge.
Training took place on the day before discharge and usually
required 1–2 h of nursing time at the bedside. A visit to the home
was usually scheduled for the day of discharge and whenever
required thereafter. Training the patient to administer the
antibiotics safely was the main focus of ASIS. However, in
situations where patients were unable to self-administer anti-
biotics, training was provided to the carer. The majority of patients
were able to return to work or studies whilst on ASIS, provided
their infection did not pose functional limitations. Only four of the
144 patients were unable to self-administer and did not have
carers who could be trained to administer antibiotics. Nursing staff
visited those patients’ homes daily to administer intravenous
antibiotics. The inability to self-administer was not a criterion for
exclusion from OPAT care. Patients treated by ASIS were under the
care of an infectious diseases team and were required to attend a
weekly clinic where they were reviewed by an infectious diseases
specialist or a registrar.
3. Results
In 2011, 150 OPAT episodes were treated by ASIS in
144 patients. One hundred and six patients (74%) were male.
The median age was 55 years (range 16–90 years). Hypertension
was the most common comorbidity, occurring in 59 patients (40%),
followed by diabetes mellitus (37 patients, 25%), ischaemic or
valvular heart disease (30 patients, 21%), and chronic kidney
disease (25 patients, 17%). Forty-two percent of patients had at
least two or more comorbidities. All patients had a PICC line
inserted for the administration of intravenous antibiotics.
The patient self-administration model was used in 140 patients
and the nursing administration model in the remaining four
patients. During the 12-month period, 466 home visits were made
for 84 patients. Sixty-six patients did not require home visits
during their OPAT care. The median duration of time spent on
patient/carer training was 105 min.
3.1. Diagnoses and microbiology
Bone and joint infections (BJI) were the most common primary
diagnoses, occurring in 71 patients (47%). Osteomyelitis accounted
for 85% of BJI and septic arthritis for 15%. Other diagnoses were
infective endocarditis (13 patients, 9%), infected intravascular
catheters (12 patients, 8%), skin and soft tissue infection
(10 patients, 7%), surgical site infection (10 patients, 7%), blood
stream infection (nine patients, 6%), central nervous system
infection (six patients, 4%), and intra-abdominal infection (six
patients, 4%). Table 1 summarizes patient demographics and
diagnoses.
Causative organisms were identiﬁed from blood cultures,
surgical specimens, or wound swabs. A conﬁrmatory microbiolog-
ical diagnosis was made in 130 patients (87%). Twenty (13%)
patients were recorded as having ‘no growth’ from cultures.
Polymicrobial infection was present in 27 patients (18%). The most
frequent microorganism isolated was Staphylococcus aureus, found
in 72 patients (48%). Methicillin-resistant S. aureus (MRSA) was
isolated in nine patients (6%). Of the nine MRSA isolates, seven
Table 1
Patient demographics and diagnoses of all patients treated by ASIS
Receiving ASIS, n (%)
Episodes (n) 150
Median age in years (range) 55 (16-90)
Males 106 (74)
Comorbidities
Hypertension 59 (40)
Diabetes mellitus 37 (25)
Ischaemic or valvular heart disease 30 (21)
Chronic kidney disease 25 (17)
Chronic lung disease 21 (14)
Other chronic illness 47 (31)
Number of comorbidities
0 44 (29)
1 43 (29)
2 26 (17)
3 or more 37 (25)
Diagnosis
Bone and joint infections 71 (47)
Infective endocarditis 13 (9)
Infected intravascular catheter 12 (8)
Skin and soft tissue infection 10 (7)
Surgical site infection 10 (7)
Blood stream infection 9 (6)
Central nervous system infection 6 (4)
Intra-abdominal infection 6 (4)
Lung/renal/liver abscess 5 (4)
Empyema 3 (2)
Other 5 (3)
ASIS, Alternate Site Infusion Service.
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were the Enterobacteriaceae, identiﬁed in 15 patients (10%),
including Enterobacter spp in six (4%), Klebsiella spp in four (3%),
Escherichia coli in two (1%), and Serratia marcescens in two (1%).
Pseudomonas aeruginosa was isolated in 14 patients (9%),
Streptococcus spp in nine (6%), anaerobes in nine (6%), Enterococcus
spp in eight (5%), other Staphylococcus spp in eight (5%), and mixed
enteric bacteria in ﬁve (3%). Figure 1 illustrates the causative
organisms in graphical format.
3.2. Antimicrobial therapy and duration
One hundred and sixty-two antimicrobials were prescribed for
the 150 episodes of care. One hundred and ten (76%) patients were
continued on oral antibiotics upon completion of the intravenous
course. Twelve (8%) patients were treated with more than one
antimicrobial at the same time. Continuous intravenous infusions
were used in 119 (74%) episodes and intermittent bolus
administration in 43 (36%). As a class, beta-lactam antibiotics
were the most frequently prescribed. Flucloxacillin was the most
common antibiotic used and was prescribed in 57 patients (35%),0 20 40 60 80
MSSA
Other
Enterobacteriaceae 
Pseudo monas
Streptococ cus sp
Anaerobes
MRSA
Staphylococcus sp
Enterococcus
Mixe d enter ics
Total nu mber
Figure 1. Principle organisms treated in 2011 by ASIS (MRSA, methicillin-resistant
Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus).followed by ticarcillin–clavulanic acid in 31 patients (19%).
Vancomycin was used to treat 17 patients (10%), benzylpenicillin
for 12 (7%), ceftriaxone for 11 (7%), ertapenem for nine (6%),
meropenem for eight (5%), cefazolin for six (4%), ceftazidime for
four (2%), lincomycin for three (2%), and teicoplanin for one (1%).
Vancomycin was administered as a continuous infusion in four
patients and as intermittent boluses in 13 patients. Trough levels
were assessed weekly and the median trough level was 16 mg/L
(range 9–35). Figure 2 demonstrates the antibiotics prescribed in
graphical format.
The total number of inpatient bed-days saved by administration
of intravenous antibiotics outside the hospital was 3520. The
median duration on ASIS was 22 days (range 4–106 days). Blood
stream infections were on the programme for a median of 25 days,
BJI for 23 days, surgical site infections for 22 days, complicated soft
tissue infections for 16 days, and infective endocarditis for 15 days.
There were 10.7 patients on average on the ASIS programme at any
one time, being cared for by four full-time equivalent ASIS nurses
who were on-call 7 days a week. Figure 3 illustrates the duration of
treatment for the different infections in graphical format and the
split between inpatient and OPAT.
3.3. Adverse events
There were 11 (7%) drug-related adverse events, one of which
resulted in patient re-admission to hospital. The rest were
managed with symptomatic treatment, earlier cessation, or a
change of antibiotic. The most common drug-related adverse event
was rash, accounting for six out of the 11 drug-related adverse
events. Flucloxacillin (three patients) was the most common
culprit, followed by vancomycin (two patients) and cefoxitin (one
patient). A switch to a different antibiotic was necessary for four
patients who developed a rash whilst on OPAT; two patients who
developed a rash had their antibiotics ceased earlier than intended
(Table 2).
One patient developed biliary lithiasis secondary to ceftriaxone,
which resolved after ceftriaxone was ceased earlier than intended.
Drug fever occurred in one patient treated with ticarcillin–
clavulanic acid. The patient was admitted to hospital for further
investigations and antibiotics were ceased in hospital. Acute
kidney injury due to gentamicin occurred in one patient treated for
enterococcal endocarditis. The other case of acute kidney injury
was presumed ﬂucloxacillin-induced interstitial nephritis, which
resolved after the antibiotic was switched to cefazolin.
Line-related adverse events occurred in ﬁve (3%) patients or 1.4/
1000 catheter-days.  There were two PICC line infections, which
resulted in cessation of antibiotics earlier than planned. In both cases,
the diagnosis of line infection was made on clinical suspicion and
neither of them resulted in detectable bacteraemia. This line-related0 10 20 30 40 50 60
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Figure 2. Antibiotics prescribed in 2011 by ASIS.
Figure 3. Duration of treatment for various infections treated by ASIS in 2011.
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programmes described in the literature.21,25 Two patients had
problems with lymphatic leakage from their PICC line, which was
managed with additional dressings. Intravenous antibiotics were
continued for the planned duration in both cases. One patient was re-
admitted to hospital for re-insertion of the PICC line as it fell out
inadvertently. The line-related sepsis rate in our study is similar to
other published results.18,24
3.4. Outcome
The overall cure rate in our study was 93%. ASIS-related re-
admissions occurred in nine patients within 28 days of cessation of
intravenous antimicrobials. Six of those re-admissions were due to
clinical deterioration requiring source control or surgical debride-
ment and one re-admission was due to clinical failure on current
antibiotics requiring a change of antimicrobial therapy. There was
one drug-related re-admission and one line-related re-admission.
On multivariate analysis, patients with two or more comorbidities
had an increased risk of failure (OR 2.15, 95% CI 1.28–3.65;
p = 0.004).
4. Discussion
We describe a patient- or carer-administered OPAT model run
by a multidisciplinary team through the Infection Management
Service at the Princess Alexandra Hospital. To our knowledge, this
is the ﬁrst study from Australia that has speciﬁcally evaluated the
outcomes of S-OPAT. In line with other international published
data, our study shows that patient- or carer-administered OPAT is a
safe and effective option for the management of selected patients
with serious infection.17,20,21
The median age of the patient cohort in our study is similar to
previous studies; however the male to female ratio is higher.10,21–23
In accordance with other published data, BJI were the most
commonly treated infections.10,17,21,24 S. aureus was the mostTable 2
Outcome of patients treated by ASIS
Outcome No. of patients (%)
Clinical cure 140 (93)
Failure 10 (7)
Re-admission 9 (6)
Inadequate source control 6 (4)
Inappropriate antibiotic 1 (0.6)
Drug-related adverse event 1 (0.6)
Line-related adverse event 1 (0.6)
ASIS, Alternate Site Infusion Service.commonly isolated organism, but the proportion of MRSA in our
study was lower than those reported in similar published studies.10,23
Antibiotic prescribing in our programme was concordant with
our hospital prescribing guidelines and the choice of antibiotic was
not made solely on the basis of dosing convenience. Narrow-
spectrum beta-lactam antibiotics were used where possible to
match the culture-proven microbiological diagnoses. Flucloxacillin
was the most frequently used antibiotic and was prescribed in
57 patients (35%). Cefazolin and ceftriaxone were only prescribed
in six (4%) and 11 (7%), respectively. In the majority of published
studies, vancomycin, ceftriaxone, and cefazolin were most
frequently prescribed due to the convenience of a once- or
twice-daily dosing regimen. All patients in our cohort had a PICC
line for the administration of antibiotics. Line-related complica-
tions were uncommon, similar to previously reported studies,
which have shown that these adverse events are not necessarily
increased in S-OPAT.24
The overall median duration of OPAT was 22 days (range 4–106
days). The median duration of OPAT was highest for bacteraemia
and BJI, and lowest for infective endocarditis. Princess Alexandra
Hospital is a referral centre for cardiac surgery and most patients
with infective endocarditis had completed a signiﬁcant proportion
of their prescribed antibiotic therapy in hospital whilst undergoing
surgical therapy. Patients who did not have cardiac surgery usually
required medical and surgical assessment and stabilization for a
period of time as inpatients prior to commencing OPAT.
The clinical outcome in our study was excellent, with cure
achieved in 93% of patients despite complicated baseline diagno-
ses. Most treatment failures occurred in complex surgical patients
who required repeated surgical treatment for better source
control; hence the treatment of these patients in an outpatient
setting did not necessarily result in clinical failure. In our study,
outcomes were only measured for 28 days post cessation of OPAT.
A longer duration of follow-up would detect clinically signiﬁcant
late relapses following the cessation of OPAT.
The nursing staff spent signiﬁcant time in our OPAT on patient
or carer training. Most patients in our cohort had complicated
infections, unlike those recruited in other studies in which
cellulitis was the most frequently treated infection through
OPAT.20,23,25 As most patients require at least a day or two to
become proﬁcient in self-administering parenteral therapy, our
OPAT programme is not likely to shorten the length of stay for
patients with cellulitis. Most patients in our programme had
complicated infections that required some days in hospital for the
initial management; hence the time spent in training patients to
self-administer antibiotics did not necessarily lengthen their
overall hospital stay.
The OPAT model of care is important in developed countries like
Australia where healthcare costs and the demand for inpatient care
are rising in the context of limited hospital bed supply. The
possibility of reducing healthcare-acquired infections and reduc-
ing the costs of inpatient care whilst maintaining patient
autonomy has led to increasing interest in OPAT services, with
many organizations now being set targets to achieve.5,26
The total costs incurred by our OPAT service were reduced by
the low number of home visits our nursing staff made over the
12 months. The cost of our OPAT, excluding drug administration
and home visits, is estimated to be approximately A$ 150.00 per
day, signiﬁcantly lower than the cost of an inpatient bed, which is
estimated to be A$ 500–800 per day depending on the Diagnosis
Related Groups (DRG).25 Patients enrolled in our OPAT lived on
average 20 km (range 1–58.2 km) away from the hospital. If all
patients were managed with the nursing administered model of
care, there would have been approximately 3300 home visits
during the year, as opposed to the 466 home visits made during the
year through our OPAT.
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